Stem Cell: Sernova Gets New Patent

Sunday, July 20, 2008

Dear manoj kumar valluru,

Last week the Canadian company Sernova was issued a patent covering the use of Sertoli cells to deliver essentially any gene in vivo (#7,399,751) without evoking an immune response. Given that the company already has clinical proof of concept data on its lead product, Sertolin, for treatment of Type I Diabetes, this will be an interesting one to watch. Speaking of immunology, a very unorthodox approach to treating neural injury was presented in a patent (#7,399,740) covering a peptide polymer that INHIBITS T regulatory cells. Angioblast Systems scored nicely getting a key patent on its mesenchymal precursor cell (#7,399,632).

An interesting news item, Habib's group from England reported that injection of 9 patients with autologous expanded CD34s had clinical improvement...but people (a certain scientist from Stanford) say that CD34s only make blood...how is this possible !?!? (we are being ironic).

The Stem Cell Meeting, to be held in San Francisco on September 16-17, 2008, is returning for its 3rd year. This conference will examine the up to date most critical scientific, policy and business issues facing stem cell research, medicine and investment. In collaboration with the leaders of the City of San Francisco and the California Institute of Regenerative Medicine, it brings together an international assembly of scientists, clinicians, policymakers and business leaders who share their vision and passion for the life sciences’ most promising field.

This Stem Cell Meeting is the premier international event bringing together world-renowned scientists at the frontier of embryonic and adult stem cell research with decision-makers and thought leaders in policy, ethics, patient advocacy, finance, business, and media to explore the challenge and promise of stem cell research and the compelling potential of emerging therapies.

StemCellPatents.com is proud to be a supporter of the The Stem Cell Meeting.

Production of a biological factor and creation of an immunologically privileged environment using genetically altered Sertoli cells

Patent Number: 7,399,751

Assignee | Inventor

This is a patent with priority in 1999 describing the use of genetically modified Sertoli cells for immune protection of implanted cells AND the use of the Sertoli cells themselves as the vector...genetic engineer with any gene is covered.

This patent is part of the Canadian company Sernova's ([Read More]

Ask a question OR leave your comments.

Clinical Trial of CD34 Stem Cells for Liver Failure

Sunday July 20th, 2008 @ 15:05:23 EST

London, UK-

The use of stem cells to treat liver failure is not new. Animal models, as well as pilot clinical trials have demonstrated statistically significant improvement in liver enzyme values and overall clinical scores.

In a recent study (Pai et al...[Read More]

Ask a question OR leave your comments.

Read more StemCellPatents.com News